Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does IPILIMUMAB Cause C-reactive protein increased? 167 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 167 reports of C-reactive protein increased have been filed in association with IPILIMUMAB (YERVOY). This represents 0.5% of all adverse event reports for IPILIMUMAB.

167
Reports of C-reactive protein increased with IPILIMUMAB
0.5%
of all IPILIMUMAB reports
19
Deaths
123
Hospitalizations

How Dangerous Is C-reactive protein increased From IPILIMUMAB?

Of the 167 reports, 19 (11.4%) resulted in death, 123 (73.7%) required hospitalization, and 34 (20.4%) were considered life-threatening.

Is C-reactive protein increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for IPILIMUMAB. However, 167 reports have been filed with the FAERS database.

What Other Side Effects Does IPILIMUMAB Cause?

Death (3,710) Malignant neoplasm progression (3,296) Diarrhoea (2,557) Off label use (2,097) Colitis (1,988) Pyrexia (1,796) Rash (1,556) Fatigue (1,447) Intentional product use issue (1,329) Nausea (1,169)

What Other Drugs Cause C-reactive protein increased?

METHOTREXATE (5,999) ADALIMUMAB (4,579) RITUXIMAB (4,060) ETANERCEPT (3,922) TOCILIZUMAB (3,719) INFLIXIMAB (3,621) LEFLUNOMIDE (3,574) HYDROXYCHLOROQUINE (3,552) ABATACEPT (3,451) SULFASALAZINE (3,096)

Which IPILIMUMAB Alternatives Have Lower C-reactive protein increased Risk?

IPILIMUMAB vs IPRAGLIFLOZIN L-PROLINE IPILIMUMAB vs IPRATROPIUM IPILIMUMAB vs IPRATROPIUM\IPRATROPIUM ANHYDROUS IPILIMUMAB vs IPTACOPAN IPILIMUMAB vs IRBESARTAN

Related Pages

IPILIMUMAB Full Profile All C-reactive protein increased Reports All Drugs Causing C-reactive protein increased IPILIMUMAB Demographics